Dr. Dea Belazi PharmD, MPH, PAHM

Pharmacy Consultant, Dea Belazi, PharmD, MPH, PAHM

Member of the Healthcare Council

Council Member Biography

Dea Belazi, PharmD, MPH, PAHM, is Vice President of Payer and Healthcare Solutions and Consulting Practice Leader for Wolters Kluwer Health, serving in a consulting capacity. In addition, he is Principle and Owner of Crowdhealth, a social networking website for consumers to share healthcare experiences, and AlchemiPharma, an online drug retail site. Previously, Dr. Belazi was Senior Director of Pharmacy Services for Future Scripts, a pharmacy benefits manager for Independence Blue Cross. Prior to that, Dr. Belazi was Associate Vice President of Clinical Programs for PerformRx, a pharmacy benefits manager for Keystone and AmeriHealth Mercy Health Plans. His experience includes reimbursement strategies, formulary management, health outcomes research, epidemiology and pharmacy benefit management. Dr. Belazi's responsibilities include national formulary management, disease management programs, effectiveness studies of pharmaceuticals and pharmacy benefit program implementations. (This is me - Update Profile)

Employment History

2006 - Unspecified: Pharmacy Consultant, Dea Belazi, PharmD, MPH, PAHM
2005 - 2006: Senior Director of Pharmacy Services, INDEPENDENCE BLUE CROSS
2001 - 2005: Associate Vice President, Clinical Programs, KEYSTONE MERCY HEALTH PLAN

GLG News^SM Analyses by Dea Belazi

Opinions and analyses expressed in G+ Insights are solely those of the author. See the Terms of Use for details.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Erythropoiesis Stimulating Agents could be further restricted by Payers (Medicare, PBMs, and Healthplans)

January 28, 2008

Analysis of:FDA Receives New Data on Risks of Anemia Drugs | www.fda.gov

Increased FDA warnings on ESAs, suchas Epogen, Procrit and Aranesp will provide payers the ability to further restrict these agents. Restrictions will come in the form of prior authorizations and other utilization management techniques.

Perhaps the Most Important Reason for Exubera Failure is that No One Wanted to Pay for it

October 29, 2007

Analysis of:Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com

Pfizers failure on Exubera were not of safety issues, or complicated device, or even consumer marketing problems. Their biggest issue that brought failure was the lack of payer coverage. Almost no payer in the US added Exubera to their formulary or saw any value over injectable insulin at the price being commanded by Pfizer.

WalMart Expansion of $4 generics

October 3, 2007

Analysis of:Wal-Mart Expands Offerings Of $4 Generic Drugs | online.wsj.com

WalMarts strategy on expanding $4 generics is not at a loss. They are taking a number of generics (in the hunderds) that are nominaly priced and selling them to consumers and still making a profit.

Indian Pharmaceutical Manufacturers

October 3, 2007

Analysis of:Drug discovery hits India | www.icis.com

Indian manufacturers such as Aurabindo, Reddy, Ranbaxy and others are getting on the shelves at the local pharmacies.

Request a consultation with Dea Belazi